Products for Research Use Only
RegisterLogin

Bardoxolone (Standard)

CAT: 0804-HY-14909R-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-14909R-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Bardoxolone (Standard) is the analytical standard of Bardoxolone. This product is intended for research and analytical applications. Bardoxolone is an orally active activator of nuclear regulatory factor (NRf-2) and an inhibitor of SARS-CoV-2 3CL protease. Bardoxolone inhibits SARS-CoV-2 3CL protease with an EC50 value of 0.43 μM in vero cells. Bardoxolone also inhibits necroptosis in HT-29 cells with an EC50 value of 1.30 μM by blocking necrosome formation through inhibiting phosphorylation of RIPK1 and RIPK3. Bardoxolone can be used in research on COVID-19, TNF-induced systemic inflammatory response syndrome (SIRS), and cerebral ischemia-reperfusion injury[1][2].
CAS Number
218600-44-3
Product Name Alternative
CDDO (Standard) ; RTA 401 (Standard)
UNSPSC
12352211
Target
Keap1-Nrf2; Necroptosis; Reference Standards; SARS-CoV; Virus Protease
Related Pathways
Anti-infection; Apoptosis; NF-κB; Others
Field of Research
Infection; Inflammation/Immunology; Cardiovascular Disease
Smiles
CC1(C)CC[C@@]2(C(O)=O)[C@@]([C@](C(C=C3[C@@]4(C)CC[C@]5([H])[C@]3(C)C=C(C#N)C(C5(C)C)=O)=O)([H])[C@@]4(C)CC2)([H])C1
Molecular Formula
C31H41NO4
Molecular Weight
491.66
References & Citations
[1]Sun Q, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.|[2]Wang Y, et al. Discovery of bardoxolone derivatives as novel orally active necroptosis inhibitors. Eur J Med Chem. 2021 Feb 15;212:113030.|[3]Yasemin Teksen, et al. Bardoxolone methyl attenuates acetaminophen-induced acute kidney injury by suppressing oxidative stress, inflammation and apoptosis[J]. 2024 May 29;31 (5) :372–379|[4]Kim HK, et al. Bardoxolone Methyl Ameliorates Chemotherapy-Induced Neuropathic Pain by Activation of Phosphorylated Nuclear Factor Erythroid 2-Related Factor 2 in the Dorsal Root Ganglia. Anesth Analg. 2024 Mar 1;138 (3) :664-675.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards
Clinical Information
No Development Reported

Related Products

CatalogName
HY-14909-01Bardoxolone
HY-13324-01Bardoxolone methyl
HY-P2274RArgifin (Standard)
HY-N9362REmodinanthrone (Standard)
HY-N7948RIsomaltotetraose (Standard)
HY-N7640RDeoxylimonin (Standard)
HY-N7617RToralactone (Standard)
HY-N7541RAntrodin A (Standard)
HY-N6739RBeauvericin (Standard)
HY-N6687RCalcimycin (Standard)

Alternative Products

CatalogName
FLB29884-01Bardoxolone
262095-01Bardoxolone methyl
S6647-25mgBardoxolone (CDDO)

Popular Products